Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with type 1 diabetes mellitus~Exclusion criteria:~* Age \< 18 years at screening visit;~* HbA1c \< 7.0 % or \> 10.0 % (national glycohemoglobin standardization program \[NGSP\] value) at screening visit;~* Patients less than 1 year before screening visit on any basal plus mealtime insulin;~* Patients not on stable insulin dose (±20% total basal insulin dose) in the last 30 days prior to screening visit;~* Patients using pre-mix insulins, human regular insulin as mealtime insulin and/or any glucose-lowering drugs other than basal insulin and mealtime rapid-insulin analogue in the last 3 months before screening visit;~* Use of an insulin pump in the last 6 months before screening visit and/or plan to switch to insulin pump in next 12 months;~* Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit;~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eq, laser, surgical treatment or injectable drugs) during the study period.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New formulation of insulin glargine (Type: EXPERIMENTAL): once daily in the evening on-top of mealtime insulin
- Lantus (insulin glargine) (Type: ACTIVE_COMPARATOR): once daily in the evening on-top of mealtime insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).